Bruker (NASDAQ:BRKR) issued an update on its FY18 earnings guidance on Thursday morning. The company provided EPS guidance of $1.34 to $1.38 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.34. The company issued revenue guidance of $1.889 billion, compared to the consensus revenue estimate of $1.82 billion.

Bruker (NASDAQ:BRKR) opened at $30.59 on Friday. Bruker has a 52-week low of $21.83 and a 52-week high of $36.53. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.60 and a current ratio of 2.60. The firm has a market cap of $4,918.89, a P/E ratio of 62.43, a price-to-earnings-growth ratio of 2.34 and a beta of 1.05.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Thursday, February 8th. The medical research company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.02. Bruker had a net margin of 4.45% and a return on equity of 26.58%. The firm had revenue of $530.50 million for the quarter, compared to analysts’ expectations of $506.74 million. During the same period in the previous year, the company posted $0.46 EPS. The company’s quarterly revenue was up 12.8% compared to the same quarter last year. equities analysts anticipate that Bruker will post 1.34 earnings per share for the current year.

Several equities analysts have weighed in on BRKR shares. JPMorgan Chase & Co. upgraded shares of Bruker from an underweight rating to a neutral rating and set a $28.00 price objective on the stock in a research report on Friday, November 3rd. Bank of America upgraded shares of Bruker from an underperform rating to a neutral rating and set a $34.00 price target on the stock in a report on Friday, November 3rd. Cowen restated a hold rating and set a $29.00 price target on shares of Bruker in a report on Friday, November 3rd. Citigroup boosted their price target on shares of Bruker from $29.00 to $34.00 and gave the company a neutral rating in a report on Friday, November 3rd. Finally, Zacks Investment Research upgraded shares of Bruker from a hold rating to a buy rating and set a $37.00 price target on the stock in a report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and four have given a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $32.29.

An institutional investor recently raised its position in Bruker stock. The Manufacturers Life Insurance Company grew its stake in shares of Bruker Co. (NASDAQ:BRKR) by 7.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,003 shares of the medical research company’s stock after acquiring an additional 331 shares during the period. The Manufacturers Life Insurance Company ‘s holdings in Bruker were worth $144,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 65.63% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Bruker (BRKR) Issues FY18 Earnings Guidance” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/bruker-brkr-issues-fy18-earnings-guidance/1857985.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Earnings History and Estimates for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.